On September 5, 2024, Karen Firestone, Director at Amylyx Pharmaceuticals Inc (AMLX, Financial), purchased 50,000 shares of the company, as reported in a recent SEC Filing. Following this transaction, the insider now owns a total of 55,000 shares of Amylyx Pharmaceuticals Inc.
Amylyx Pharmaceuticals Inc is engaged in the development of innovative treatments aimed at stopping the progression of neurodegenerative diseases, including ALS and Alzheimer's disease.
The purchase was made at a stock price of $2.13, valuing the transaction at $106,500. This acquisition has increased the insider's stake significantly, reflecting a strong commitment to the company's future. Over the past year, Karen Firestone has bought a total of 54,000 shares and has not sold any shares.
The recent insider buying trend at Amylyx Pharmaceuticals Inc shows a total of 4 insider buys over the past year, compared to 10 insider sells in the same period. This activity can provide insights into the sentiment of those closest to the company's operations and potential.
The stock currently holds a market cap of $171.568 million. For further valuation metrics, investors might consider the GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow to assess whether the stock is trading at a fair value.
This insider purchase could be a signal to investors about the potential undervaluation or future prospects of Amylyx Pharmaceuticals Inc, considering the insider's increasing investment in the company.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
